# Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Caicun Zhou,Yi‐Long Wu,Gongyan Chen,Jifeng Feng,Xiao-Qing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lü,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jianan Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,L Zhang,Changxuan You |
| Citations | 4,112 |
| DOI | 10.1016/s1470-2045(11)70184-x |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2160982674 |
| PMID | 21783417 |
| Type | article |
| Year | 2011 |

## Paper authors

- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.